Nebenwirkungen · Arixtra
Arixtra 5 mg/0.4 ml solution for injection, pre-filled syringe. · Abschnitt 4.8 · PDF-Seite 34–35
HOS-110160 · Präparat HOS-093307
34 In addition, 8 patients (2.2%) had overt bleeding for which a blood product was administered, and which was not directly attributable to the patient’s underlying medical condition and 4 patients (1.1%) had bleeding that required medical or surgical intervention. All these events warranted either interruption or withdrawal of fondaparinux treatment except for 1 patient for whom the action taken with fondaparinux was not reported. An additional 65 patients (17.8%) reported other overt bleeding events or menstrual bleeding resulting in a medical consultation and/or intervention.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-07T11:30:00Z · SHA-256 381af76ffd2bbb8fff8013d6d98ed50ab7a9f4fb8da38de9af66e45dcfd01fac · Passage 4be31a3d32f19b2ac6562837f5a068a24aa7f3e725b0a4b13b217e728c42d88a · Zeichen 6512–7098 im Abschnitt